Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis
Abstract Background The reimbursement of erenumab in Spain and other European countries is currently restricted because of the cost of this novel therapy to patients with migraine who have experienced previous failures to traditional preventive treatments. However, this reimbursement policy should b...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2024-03-01
|
| coleção: | The Journal of Headache and Pain |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s10194-024-01747-w |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|